SMARCB1 and sarcoma: Two patients each with refractory, metastatic, sarcoma NOS harboring a SMARCB1 deletion (Fig. 6a) and BRAFV600E (Fig. 6b) had a durable partial response to tazemetostat, an EZH2 inhibitor and a rapid response to vemurafenib and trametinib, respectively.